NRX Pharmaceuticals (NRXP) Operating Expenses (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Operating Expenses of $5.8 million for Q1 2026, up 51.03% year-over-year from $3.8 million in Q1 2025, and up 3.62% quarter-over-quarter from $5.6 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Operating Expenses (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Operating Expenses for 10 consecutive years, with $5.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 51.03% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $19.4 million (up 18.73% YoY), while the FY2025 annual figure was $17.4 million, down 5.69% from the prior year.
- Operating Expenses advanced to $5.8 million in Q1 2026 per NRXP's latest filing, from $5.6 million in the prior quarter.
- Across five years, Operating Expenses topped out at $15.7 million in Q1 2022 and bottomed at $2.4 million in Q4 2024.
- Historically, Operating Expenses has averaged $6.4 million across 5 years, with a median of $5.8 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Expenses sank 81.33% — and 2025, when it surged 130.55%.
- NRX Pharmaceuticals' Operating Expenses stood at $9.9 million in 2022, then slumped by 55.44% to $4.4 million in 2023, then sank by 44.8% to $2.4 million in 2024, then soared by 130.55% to $5.6 million in 2025, then increased by 3.62% to $5.8 million in 2026.
- Business Quant data shows NRXP's Operating Expenses at $5.8 million in Q1 2026, $5.6 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 7.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.81 Mn |
| Dec 31, 2025 | 5.61 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Mar 31, 2025 | 3.85 Mn |
| Dec 31, 2024 | 2.43 Mn |
| Sep 30, 2024 | 3.02 Mn |
| Jun 30, 2024 | 7.05 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 4.41 Mn |
| Sep 30, 2023 | 5.81 Mn |
| Jun 30, 2023 | 8.19 Mn |
| Mar 31, 2023 | 3.85 Mn |
| Dec 31, 2022 | 9.89 Mn |
| Sep 30, 2022 | 9.14 Mn |
| Jun 30, 2022 | 9.60 Mn |
| Mar 31, 2022 | 15.71 Mn |
| Dec 31, 2021 | 52.98 Mn |
| Sep 30, 2021 | 20.10 Mn |
| Jun 30, 2021 | 17.12 Mn |